Promising Results for Bendamustine/Rituximab Plus Polatuzumab Vedotin in Lymphomas

Jonathon B. Cohen, MD

Jonathon B. Cohen, MD, discusses findings from a study of polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, with bendamustine and rituximab in patients with aggressive lymphomas.

Jonathon B. Cohen, MD, assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, Winship Cancer Institute, discusses findings from a study of polatuzumab vedotin, an anti-CD79b antibody-drug conjugate, with bendamustine (Bendeka) and rituximab (Rituxan) in patients with aggressive lymphomas.

In this randomized phase II study, all patients received bendamustine/rituximab, and some patients were randomized to receive polatuzumab vedotin. Cohen says there was an impressive improvement in both progression-free survival and overall survival compared to the control arm, as well as higher complete response rates.